Annals of Clinical and Translational Neurology

OCT 12, 2026 · REVIEW

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

Annals of Clinical and Translational Neurology

The glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glyce

OCT 6, 2026 · JOURNAL ARTICLE

Anticoagulation Treatment Response Among Phenotypic ESUS Clusters: Evidence From CASPR

Annals of Clinical and Translational Neurology

ABSTRACT Objective To evaluate treatment effect heterogeneity across phenotypic clusters of patients with cryptogenic embolic stroke using causal inference methods. Methods From a

OCT 4, 2026 · JOURNAL ARTICLE

Copine‐4 Paraneoplastic Autoimmune Encephalitis

Annals of Clinical and Translational Neurology

ABSTRACT We characterize copine‐4 (CPNE4)‐IgG and report clinical associations. Among 844 samples with unclassified neural IgGs identified by mouse‐brain indirect immunofluorescenc

AUG 6, 2026 · JOURNAL ARTICLE

Safety and Efficacy of GLP ‐1 Receptor Agonists in Adults With Epilepsy, Obesity, and Type 2 Diabetes

Annals of Clinical and Translational Neurology

Retrospective cohort study with propensity matching showing GLP-1 RAs safe for seizure control and effective for weight loss in epilepsy patients, but limited by observational design and inability to detect smaller harmful effects.